GLP-1 2.0: Amylin and Orals Ranked After Lilly's $1.05T Run

Everyone already owns the injectable GLP-1 winners, and that is the problem. Eli Lilly trades near $1.05 trillion and Novo Nordisk near $205 billion. That is $1.26 trillion of combined market cap that assumes semaglutide, tirzepatide, and the next generation of incretin drugs keep compounding forever. The incumbent GLP-1 market is fully priced. The second-order trade, the companies fixing what GLP-1 1.0 got wrong, is where the multiples are still sane. This setup has played out before. Once a category leader becomes a trillion-dollar asset, the next hundred billion gets made by whoever fixes its biggest flaw.

The flaw is muscle. Across the major GLP-1 trials, 25% to 40% of total weight loss is lean mass rather than fat. In the Phase 2 BELIEVE study, semaglutide 2.4 mg produced a 7.4% decline in total body lean mass at 72 weeks. For a 65-year-old with limited muscle reserve, that is the difference between functional independence and a fall. The anti-myostatin roundup covers one lane of the fix. The two lanes the market has not fully priced are amylin analogs that add satiety while blunting the muscle and GI side-effect tradeoff, and oral GLP-1s that kill the injection burden. Prices below are from Polygon’s August 29 close.

Eli Lilly: The Full-Stack Player, $1.05 Trillion

Lilly does not need to win the second wave because it already owns most of it. Retatrutide, the triple agonist that hits GIP, GLP-1, and glucagon, is the efficacy leader of the entire field. In the TRIUMPH-3 Phase 3 trial, the 12 mg dose produced 22.6% weight loss at 80 weeks in severe obesity, with triglycerides down 37%, non-HDL cholesterol down 16.5%, and hsCRP down 51.2%. The BLA is planned for Q1 2027, and the only reason it is not sooner is chemistry, manufacturing, and controls paperwork, not the data. TRIUMPH-2, the diabetes arm, showed 20.8% weight loss and cut A1C by up to 1.6 points, and the cardiovascular signals matter more than the pounds: major adverse cardiovascular events trended 18% lower with a hazard ratio of 0.82 and systolic blood pressure fell 9.3 mmHg.

The oral lane is Lilly’s too. Foundayo (orforglipron), the first and only GLP-1 pill for weight loss, won FDA approval on April 1, 2026 and delivered 12.4% weight loss at the highest dose in ATTAIN-1. Lilly launched it at $25 a month with commercial coverage and $149 self-pay, which is how an oral undercuts an injectable on price. And Lilly’s amylin asset, eloralintide, is early-stage, but its combination data with Zepbound has reignited the amylin design debate. The verdict on Lilly is boring and correct: it owns the space, and the second wave will not move a $1.05 trillion stock. Retatrutide is already in the price. You own Lilly for the compounding, not for the catalyst.

Novo Nordisk: CagriSema Won, Then Lost, $205 Billion

CagriSema, the fixed-dose combination of the amylin analog cagrilintide and semaglutide, is Novo’s answer to the muscle-loss and efficacy ceiling. In REDEFINE 1, published in the New England Journal of Medicine, CagriSema 2.4/2.4 mg produced 22.7% weight loss at 68 weeks, with 40.4% of patients reaching at least 25% loss. That is the top of the range for any approved obesity drug.

Then came the head-to-head. In REDEFINE 4, the open-label trial against tirzepatide 15 mg, CagriSema delivered 23.0% weight loss at 84 weeks versus 25.5% for tirzepatide. It missed the non-inferiority bar. And the muscle-loss thread is not fully solved here either. In a REDEFINE 1 subset, CagriSema cut fat mass 35.7% but also cut lean soft-tissue mass 14.4%, a smaller share of total loss than semaglutide alone but still not zero. Novo’s flagship second-wave asset is a strong number two, not the leader. Amycretin, Novo’s oral amylin and GLP-1 co-agonist, is still early. Novo is defending its franchise rather than extending it, and at $205 billion it is priced more like a leader than a number two.

Zealand Pharma: The Purest Amylin Play, $3.3 Billion

This is the name where the second-wave thesis is cleanest and the multiple is cheapest. Petrelintide, Zealand’s amylin analog, delivered 10.7% mean weight loss at 42 weeks versus 1.7% for placebo in the ZUPREME-1 Phase 2 trial, with placebo-like tolerability and 98% of patients reaching the maintenance dose. The secondary endpoints fill in the picture: waist circumference fell 7.9 to 10.8 centimeters versus 4.3 on placebo, hsCRP dropped 17% to 41% versus 6%, and triglycerides fell 12% to 21% versus 9%. That weight loss trails Wegovy and Zepbound, but the tolerability is the point: amylin works through satiety rather than nausea, and that is the profile that could win for the patients who cannot stomach a full-dose GLP-1.

Roche partnered on petrelintide and the two are advancing it to Phase 3. The catch is the listing. Zealand trades on Nasdaq Copenhagen under ZEAL, and the U.S. ticker, ZLDPF, is an OTC line that moves a few hundred shares a day. At a $3.3 billion market cap, the catalyst is real but the investable U.S. pure play barely exists. That is the difference between a thesis and a trade.

Roche: The Oral GLP-1 Challenger, $360 Billion

Roche bought Carmot Therapeutics for $2.7 billion to get enicepatide, an oral GLP-1 that showed 22.5% placebo-adjusted weight loss in Phase 2 with no plateau at 48 weeks. That is the profile that matters: orforglipron already set the oral bar at 12.4%, and enicepatide is aiming well above it. The problem is timeline and scale. Roche’s obesity filing is not expected until 2028, and at a $360 billion market cap, enicepatide is a rounding error either way. Roche is also the petrelintide partner, which gives it two shots in the second wave, both immaterial to the stock.

Pfizer: The Cautionary Tale, $160 Billion

Pfizer is what happens when a diversified pharma arrives late and pays up. It spent roughly $10 billion on Metsera in early 2026, then axed two of the three obesity assets within a quarter. Danuglipron, the oral GLP-1 Pfizer had spent years on, was discontinued entirely. What is left is berobenatide, an injectable GLP-1 with monthly dosing that showed 12.3% placebo-adjusted weight loss at 28 weeks in Phase 2b. First approval is not expected until 2028, and monthly dosing is a convenience feature, not a differentiated mechanism. A $10 billion bet on a me-too injectable arriving two years after the market is settled is how you underperform. Pfizer is an avoid.

The Risk

A broader point worth internalizing: the obesity market is splitting into efficacy and tolerability tiers. Retatrutide and CagriSema are chasing the efficacy ceiling, where every point of weight loss is priced in advance. The amylin and oral lanes are chasing tolerability and convenience, where the differentiation is patient experience rather than a number on the scale. The second tier is harder to value, which is exactly why the multiples are still sane there.

Obesity is also a winner-take-most market. A single failed Phase 3 in the second wave resets the entire lane, because the drugs are all chasing the same patient and the same payer. The specific risk to watch is the oral lane: orforglipron is already approved at 12.4%, which sets a floor that any latecomer has to clear. Anyone who arrives in 2028 with less efficacy and a worse side-effect profile will not sell.

The Verdict

Ranked by risk-reward over the next 12 to 18 months:

1. Lilly is the buy-and-hold winner, but it is not a second-wave trade. Own it for retatrutide compounding, and accept that a $1.05 trillion stock will not move on any single catalyst.
2. Zealand is the purest amylin expression and the cheapest multiple in the list, but the U.S. listing is illiquid. This is a thesis you can own only through Copenhagen or a patient OTC position.
3. Novo is a hold. CagriSema is a strong number two that just lost its head-to-head, and the stock is priced like a leader.
4. Roche is a hold for the diversified investor; enicepatide and petrelintide are real but immaterial to a $360 billion company.
5. Pfizer is an avoid. A $10 billion late-arrival bet on a me-too injectable is the worst risk-reward in the group.

The second wave is real. The muscle-loss and injection-burden flaws are genuine, and the companies fixing them will create the next hundred billion in value. The mistake is assuming the trillion-dollar incumbents are the way to play it. They are not. The trade is the fix, not the incumbent, and the fix is where the valuations still have room to run.